Description: Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Home Page: www.akerotx.com
AKRO Technical Analysis
601 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 487 6488
Officers
| Name | Title |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | Pres, CEO & Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Exec. VP, COO & Sec. |
| Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer |
| Mr. William R. White J.D. | Exec. VP, CFO, Treasurer & Head of Corp. Devel. |
| Ms. Catriona Yale | Exec. VP & Chief Devel. Officer |
| Mr. John J. Schembri | VP of Fin. & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0267 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |